Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ReNetX Bio logo — Pioneering therapeutics to address injuries and damages in t...

ReNetX Bio

Pioneering therapeutics to address injuries and damages in the central nervous system, including spinal cord injuries and glaucoma.

Founded 2010 United States New Haven, United States 3 employees Venture round Total: $9.80M Biotechnology, Health Care +1

General Information

Company Name ReNetX Bio
Founded Year 2010
Location United States New Haven, United States
Employees 3
Industries Biotechnology, Health Care, Information Technology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ReNetX Bio. To contact ReNetX Bio, visit renetx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ReNetX Bio compare?

A PDF of ReNetX Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ReNetX Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ReNetX Bio

ReNetX Bio is a pioneering biotechnology startup focused on developing therapeutics for addressing injuries and damages in the central nervous system (CNS), with a particular emphasis on spinal cord injuries and glaucoma. The company's mission is centered around providing first-in-class treatments for conditions such as spinal cord injury, glaucoma, and traumatic brain injury. At the forefront of their efforts is AXER-204, a potential game-changing treatment designed to rebuild connections between healthy and damaged neurons by blocking receptors that inhibit axonal growth. ReNetX Bio, founded in 2010, is currently on the cusp of entering Phase 2 testing. The startup operates within the biotechnology, healthcare, and information technology industries, with its headquarters situated in the United States. In their most recent funding round, ReNetX Bio secured a significant $2.80M investment in a Venture Round that took place on 28 September 2020. Despite the absence of specific investors for the last investment, the startup's advancements and groundbreaking approach to CNS therapeutics position it as a promising opportunity for venture capital firms seeking disruptive and impactful investments in the biotechnology space.

Business keywords: therapeutics, central nervous system, spinal cord injury, glaucoma, neurological damage, AXER-204, Phase 2 testing, neuron regeneration, CNS injuries, innovation, biomedical research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.80M -
28 Sep 2020
Series A Undisclosed 2
Connecticut Innovations Spring Mountain Capital
Connecticut Innovations, Spring Mountain Capital
07 May 2018
Venture Round $7.00M 1
Wings for Life
07 Nov 2017

ReNetX Bio Alternatives & Competitors

View All Alternatives
ReNetX Bio vs
Neuralstem, Inc.
Neuralstem, Inc.

Advancing stem cell technology to treat central nervous system diseases and deliver hope for incurab...

Post-IPO Equity
3 employees
Biotechnology, Health Care
ReNetX Bio vs
Novoron Bioscience
Novoron Bioscience United States

Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spi...

Seed
17 employees
Biopharma, Biotechnology
ReNetX Bio vs
Disarm Therapeutics
Disarm Therapeutics

Creating advanced therapeutics to combat axonal degeneration and treat neurological diseases since 2...

Series A
Biotechnology, Health Care
View all alternatives

FAQ About ReNetX Bio

Pioneering therapeutics to address injuries and damages in the central nervous system, including spinal cord injuries and glaucoma.
ReNetX Bio was founded in 2010.
ReNetX Bio is headquartered in New Haven, United States.
ReNetX Bio operates in Biotechnology, Health Care and Information Technology. Its work centres on therapeutics, central nervous system, spinal cord injury and glaucoma.
ReNetX Bio has approximately 3 employees.
ReNetX Bio has completed 3 funding rounds, raising a total of $9.80M. The latest funding stage is Venture round.
Top alternatives and competitors to ReNetX Bio include Neuralstem, Inc., Novoron Bioscience, Disarm Therapeutics, Umecrine Cognition AB, Luxna Biotech Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ReNetX Bio and Neuralstem, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ReNetX Bio, https://bouncewatch.com/company/renetx-bio, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout